A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer.
- Author:
Sang Byung BAE
1
;
Nam Su LEE
;
Han Jo KIM
;
Kyoung Ha KIM
;
Hyun Jung KIM
;
Chan Kyu KIM
;
Kyu Taeg LEE
;
Sung Kyu PARK
;
Jong Ho WON
;
Dae Sik HONG
;
Hee Sook PARK
Author Information
1. Division of Hematology and Oncology, Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea. mdnslee@hosp.sch.ac.kr
- Publication Type:Original Article
- Keywords:
Irinotecan;
5-Fluorouracil;
Leucovorin;
Colorectal neoplasms
- MeSH:
Colorectal Neoplasms*;
Disease Progression;
Fluorouracil*;
Humans;
Leucovorin*;
Neutropenia;
Prospective Studies
- From:Cancer Research and Treatment
2006;38(2):72-77
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We prospectively conducted a non-randomized phase II trial to evaluate the efficacy and safety of combination irinotecan, leucovorin (LV) and 5-fluorouracil (FU) as a first-line regimen for treating patients with previously untreated advanced colorectal cancer (CRC). MATERIALS AND METHODS: Twenty-six previously untreated patients with advanced, recurrent or metastatic CRC were enrolled in this study. The patients received either irinotecan 180 mg/m2 on day 1 with LV bolus of 200 mg/m2 and FU bolus of 400 mg/m2, and this was followed by FU continuous infusion of 600 mg/m2 on day 1 and day 2 (the FOLFIRI regimen), or they were treated with LV bolus of 400 mg/m2 and FU bolus of 400 mg/m2 followed by FU continuous infusion of 2,400 mg/m2 for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression. RESULTS: The objective response rate was 23.1% (6/26) respectively, for both treatments. The median time to progression was 5.3 months (range: 0.4~19.9), and the overall survival was 11.2 months (range: 0.5~52.3). The prognostic factor for longer survival was the Eastern Cooperative Oncology Group (ECOG) performance status (PS). The non-hematological toxicities were similar for both treatment groups, with more frequent grade > or =3 neutropenia being noted for the simplified FOLFIRI regimen. CONCLUSION: The biweekly irinotecan based regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and the ECOG PS was the independent prognostic factor.
